Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed a Current Report on Form 8-K dated March 17, 2026. The filing serves as a Regulation FD disclosure regarding an upcoming Key Opinion Leader (KOL) event focused on Duchenne muscular dystrophy (DMD).
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a disclosure of a corporate event rather than a financial report.
Material Changes
No material financial changes or operational updates were reported in this filing. The content is limited to the announcement of a scheduled webcast.
Guidance, Outlook, and Management Commentary
The Company announced a live webcast scheduled for March 17, 2026, at 9:00 a.m. Eastern Time. The event will feature:
- Aravindhan Veerapandiyan, MD (Pediatric Neurologist, University of Arkansas for Medical Sciences).
- Pat Furlong (Founding President, Parent Project Muscular Dystrophy).
Discussion topics include the unmet need and treatment landscape for DMD, an overview of the PBGENE-DMD program, and the FUNCTION-DMD Phase 1/2 clinical trial. Presentation materials are available on the Company's investor website and are furnished as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the date and time of the KOL event (March 17, 2026, 9:00 a.m. ET).
- Access the presentation materials via the Company's investor relations website under Events & Presentations.
- Note that the information in this 8-K is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
- Confirm that no financial results or guidance were included in this specific filing.